The systematic evolution of ligands by exponential enrichment (SELEX) is a powerful in vitrotechnique for discovering nucleic acid aptamers\u2014synthetic molecules that bind specific targets with antibody-like precision. By iteratively screening vast random-sequence libraries, SELEX isolates high-affinity, high-specificity aptamers for diverse targets, including proteins, small molecules, and whole cells. The integration of next-generation sequencing (NGS) has revolutionized this field, enabling data-driven, efficient aptamer development with significant advantages over traditional methods.<\/p>\n
Traditional SELEX relies on limited cloning and sequencing, often missing rare, high-performance aptamers. NGS-SELEX deeply sequences the entire pool after each selection round. By quantitatively tracking sequence enrichment, researchers can objectively identify the most promising aptamer candidates based on their enrichment kinetics, dramatically improving screening success rates.<\/p>\n
RNA aptamers often exhibit superior binding properties due to structural complexity but require tailored screening approaches. Key optimizations include:<\/p>\n
(i) Using chemically modified nucleotides to enhance library stability.<\/p>\n
(ii) Maintaining rigorous RNase-free conditions to preserve RNA integrity.<\/p>\n
(iii) Employing engineered reverse transcriptases to ensure accurate sequence conversion for sequencing.<\/p>\n
For RNA-SELEX, converting unstable RNA into high-quality NGS libraries is critical. Optimization focuses on:<\/p>\n
(i) Library Construction: Using modification-tolerant enzymes and controlled PCR to prevent sequence bias.<\/p>\n
(ii) Bioinformatics: Moving beyond simple abundance metrics to analyze sequence families, enrichment patterns, and predicted structures, enabling smarter identification of functional aptamers.<\/p>\n
As SELEX sequencing matures, its applications are expanding into new frontiers. It enables the development of precision diagnostic and therapeutic tools, such as aptamers for liquid biopsy or targeted drug delivery. Furthermore, the large-scale sequence-function data generated is ideal for training machine learning models to predict binding rules, accelerating design. Ultimately, the convergence of SELEX with single-cell and spatial omics technologies promises to unlock novel aptamer-based solutions for complex biomedical challenges.<\/p>\n
The fusion of SELEX with high-throughput sequencing and sophisticated bioinformatics represents a paradigm shift in aptamer discovery. This optimized pipeline delivers robust, high-performance aptamers faster and more reliably than ever before, paving the way for their broader adoption in therapeutics, diagnostics, and fundamental research.<\/p>\n
Read More<\/strong><\/a>!<\/p>\n Alpha lifetech<\/strong><\/a>\u00a0leveraging its established\u00a0phage display platform<\/a><\/strong>, offers flexible application of various SELEX aptamer screening strategies, including Cell-SELEX, targeting diverse entities such as proteins, whole cells, and even live animals. Furthermore, we provide end-to-end services encompassing target preparation (e.g., prokaryotic or mammalian protein expression),\u00a0aptamer screening<\/a><\/strong>, NGS sequencing analysis,\u00a0aptamer synthesis<\/a><\/strong>, and affinity validation. This integrated approach significantly shortens research timelines and accelerates the translation of your scientific discoveries.<\/p>\n","protected":false},"excerpt":{"rendered":" Advancing Aptamer Discovery: How SELEX Sequencing Transforms Biomolecular Screening The systematic evolution of ligands by exponential enrichment (SELEX) is a powerful in vitrotechnique for discovering nucleic acid aptamers\u2014synthetic molecules that bind specific targets with antibody-like precision. By iteratively screening vast random-sequence libraries, SELEX isolates high-affinity, high-specificity aptamers for diverse targets, including proteins, small molecules, and … <\/p>\n","protected":false},"author":1,"featured_media":44,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"slim_seo":{"title":"Advancing Aptamer Discovery: How SELEX Sequencing Transforms Biomolecular Screening - Alpha Lifetech","description":"Advancing Aptamer Discovery: How SELEX Sequencing Transforms Biomolecular Screening The systematic evolution of ligands by exponential enrichment (SELEX) is a p"},"footnotes":""},"categories":[7],"tags":[],"class_list":["post-399","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-targeting-ligands"],"_links":{"self":[{"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/posts\/399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/comments?post=399"}],"version-history":[{"count":1,"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/posts\/399\/revisions"}],"predecessor-version":[{"id":400,"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/posts\/399\/revisions\/400"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/media\/44"}],"wp:attachment":[{"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/media?parent=399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/categories?post=399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/tags?post=399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}